S1PR1 binds S1PR1 agonists

Stable Identifier
R-HSA-9678854
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that regulates a diverse range of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. S1P receptor 1 (S1PR1) inhibitors possess immunomodulatory/immunosuppresant actions. The S1PR1 inhibitors fingolimod (FTY720) (Chun & Hartung 2010) and siponimod (BAF312) (Pan et al. 2013, Glaenzel et al. 2018) are effective immunology modulators which are widely used in the treatment of multiple sclerosis.

Fingolimod is being investigated in the management of inflammation caused by COVID-19 (Phase 2 study NCT04280588).

Literature References
PubMed ID Title Journal Year
29735753 Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

Glaenzel, U, Jin, Y, Nufer, R, Li, W, Schroer, K, Adam-Stitah, S, Peter van Marle, S, Legangneux, E, Borell, H, James, AD, Meissner, A, Camenisch, G, Gardin, A

Drug Metab. Dispos. 2018
24900670 Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator

Pan, S, Gray, NS, Gao, W, Mi, Y, Fan, Y, Wang, X, Tuntland, T, Che, J, Lefebvre, S, Chen, Y, Chu, A, Hinterding, K, Gardin, A, End, P, Heining, P, Bruns, C, Cooke, NG, Nuesslein-Hildesheim, B

ACS Med Chem Lett 2013
20061941 Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

Chun, J, Hartung, HP

Clin Neuropharmacol 2010
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!